In the fall fo 2010, Pfizer trumpeted the purchase of a small, privately held drugmaker called FoldRx Pharmaceuticals, which developed its own discovery platform technology and was completing testing for it lead compound. The medication, which is called Tafamidis, is designed to treat familial amyloid polyneuropathy, a rare and progressively fatal genetic neurodegenerative disease. Right now ...
